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behaviour, mood, cognition and neurophysiology of children and adolescents
(aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and
inattention: study protocol ACTRN12610000978066
Abstract
Background: The prevalence rate of attention-deficit/hyperactivity disorder (ADHD) within Western
cultures is between 5% and 12%, and is the most common psychiatric illness among school-aged
children, with an estimated 50% of these children retaining ADHD symptoms for the rest of their lives.
Children with ADHD have lower blood levels of long-chain Poly Unsaturated Fatty Acids (LC PUFAs)
compared with children without ADHD, and following PUFA supplementation, have shown improvements
in ADHD-related symptoms. One highly promising marine based LC PUFA preparation is the Omega-3-rich
Lyprinol/Omega XL which is a natural formulation containing standardised lipid extract of the New
Zealand green lipped mussel (Perna canaliculus) known as PCSO-524® which contains a unique
combination of free fatty acids, sterol esters, polar lipids and carotenoids. It is this unique combination of
marine lipids that may assist in correcting the decreased levels of LC PUFA levels in children with
symptoms of ADHD. The compound is a mixture belonging to a lipid group called sterol esters (SE). The
fatty acids in the SE fraction are mainly myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic
acid, linoleic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Lyprinol/Omega XL
has previously been shown to contain a potent group of Omega-3 lipids that block the 5 - lipoxygenase
metabolic pathway responsible for inflammation in the body.
Methods: A randomized double blind placebo controlled trial will be utilized to assess the effects of 14
weeks administration of Lyprinol/Omega XL versus placebo in 150 children aged 6 to 14 years with high
levels of hyperactivity and inattention. Additionally, a range of cognitive, mood and central
electrophysiological measures will be undertaken during the 14 week supplementation trial. The primary
outcome measure, the Conners’ Parent Rating Scales will be completed initially at baseline, then in weeks
4, 8, 10, 14 and then again at 4 weeks post-administration (week 18). The results will contribute to our
understanding of the efficacy of marine based Omega-3 s with high anti-inflammatory actions on
inattention and hyperactivity in children aged 6 to 14 years.
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Abstract
Background: The prevalence rate of attention-deficit/hyperactivity disorder (ADHD) within Western cultures is
between 5% and 12%, and is the most common psychiatric illness among school-aged children, with an estimated
50% of these children retaining ADHD symptoms for the rest of their lives. Children with ADHD have lower blood
levels of long-chain Poly Unsaturated Fatty Acids (LC PUFAs) compared with children without ADHD, and following
PUFA supplementation, have shown improvements in ADHD-related symptoms. One highly promising marine
based LC PUFA preparation is the Omega-3-rich Lyprinol/Omega XL which is a natural formulation containing
standardised lipid extract of the New Zealand green lipped mussel (Perna canaliculus) known as PCSO-524® which
contains a unique combination of free fatty acids, sterol esters, polar lipids and carotenoids. It is this unique
combination of marine lipids that may assist in correcting the decreased levels of LC PUFA levels in children with
symptoms of ADHD. The compound is a mixture belonging to a lipid group called sterol esters (SE). The fatty acids
in the SE fraction are mainly myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid,
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Lyprinol/Omega XL has previously been shown to
contain a potent group of Omega-3 lipids that block the 5 - lipoxygenase metabolic pathway responsible for
inflammation in the body.
(Continued on next page)
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Methods: A randomized double blind placebo controlled trial will be utilized to assess the effects of 14 weeks
administration of Lyprinol/Omega XL versus placebo in 150 children aged 6 to 14 years with high levels of
hyperactivity and inattention. Additionally, a range of cognitive, mood and central electrophysiological measures will
be undertaken during the 14 week supplementation trial. The primary outcome measure, the Conners’ Parent Rating
Scales will be completed initially at baseline, then in weeks 4, 8, 10, 14 and then again at 4 weeks post-administration
(week 18). The results will contribute to our understanding of the efficacy of marine based Omega-3 s with high antiinflammatory actions on inattention and hyperactivity in children aged 6 to 14 years.
Keywords: Lyprinol, Omega XL, ADHD, Hyperactivity, Impulsivity, Omega 3 s, Marine oil extract, RCT

Background and rationale
Developmental disorders can have detrimental effects
on a child’s social, emotional and academic future.
Attention-deficit/hyperactivity disorder (ADHD) is the
most prevalent developmental disorder in school aged
children [1-3]. The symptoms of ADHD include hyperactivity, impulsivity, and inattention and are common
traits in other similar developmental disorders at both
clinical and sub-clinical levels [4-6]. This subclinical
group highlights an area of child mental health that is
wide-spread and largely overlooked. A child’s ability to
attend, recall and utilise learnt information inside and
outside of the classroom is vulnerable to a number of
environmental influences and genetic predispositions.
Links to dysfunctions of neuro-circuitry [7,8], neurochemistry [9], developmental deviations [10,11] and
neuronal maturation [12] have all been investigated as
suspected causes for ADHD. One treatment model is
based on the reduced levels of long chain poly unsaturated fatty acids (LC PUFAs) in the plasma of ADHD
children compared to normals [6,13-15]. This has led to
extensive research examining the efficacy of omega-3
supplementation as a natural alternative to methylphenidate (MPH e.g., Ritalin®) and other stimulant and
non-stimulant pharmaceuticals [16,17].
What is attention-deficit/hyperactivity disorder?

The prevalence rate of ADHD within Western cultures is
between 5% and 12%, representing the most common
psychiatric illness among school-aged children, with an estimated 50% of these children retaining ADHD symptoms
into adulthood and for the rest of their lives [1,3] and less
than 5% of this demographic attaining a university degree
[18]. The disorder involves a child’s inability to maintain
attention and focus and to remain calm, quiet and cooperative in both school and home settings. Symptoms of
the disorder include inattention and/or excessive hyperactivity and impulsivity. A clinical diagnosis of the
disorder involves one of three forms: Predominantly
Inattentive Type (mainly symptoms of inattention), Hyperactive-Impulsive Type (mainly excessive behaviour related

symptoms) or Combined Type (symptoms of both inattention and hyperactivity/impulsivity are clearly evident) [2].
Neurological causes of the disorder have been linked to
dysfunctions of the Prefrontal Cortex (PFC) [7,8]. The PFC
controls and moderates cognitive processes including executive functioning which includes decision making, planning and monitoring behaviours. Theories on the
dysfunction of the neuro-circuitry within the prefrontal cortex have provided some insight into potential causes and
are based on two developmental complications; maturational lag [12], or developmental deviation [10,11]. Depending on the severity of symptoms of the child, it has
also been argued that this maturational lag in most children
will gradually be reduced relative to healthy normal peers
[19]. Developmental deviation has been found in electroencephalograph (EEG) studies revealing that despite age
changes, ADHD symptoms and associated cognitive differences remain as maturation continues, suggesting an abnormal developmental path to peers [10,11]. The most
common theories describing neurochemical causes of the
disorder centre on low amounts of the catecholamine neurotransmitters dopamine and noradrenaline in the PFC
[20,21]. There has been extensive research into these causes
including genetic influences that predispose a child to deficits in dopamine (and serotonin) transmission [22]. Other
causes have been attributed to exposure of the foetus/child
to harmful agents in the prenatal, perinatal, postnatal and
early childhood phases [23]. In utero exposure to excess alcohol, tobacco and lead have been linked to an increased
risk of ADHD [4], while studies on diet have found that
ADHD symptoms may become exacerbated when certain
additives or food preservatives are consumed [24].
Stimulant medication such as methylphenidate (MPH
e.g., Ritalin®), are considered to be beneficial for ADHD
children as it is thought that administration of MPH increases levels of noradrenalin and dopamine in the PFC
[1]. Animal models have demonstrated the efficacy of
MPH by highlighting a specific mode of action of MPH
in the dorsomedial PFC and linking this to cognitive
performance in male Sprague–Dawley rats [25]. Some
studies have also demonstrated effectiveness of MPH in
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treating those children with intellectual disabilities
(IQ 30–69) and these disabilities have been known to
increase the severity of ADHD symptomology [26].
Problems with the chronic use of these medications
however, can lead to complications with appetite,
trouble sleeping and increased levels of anxiety and a
host of other unpleasant side effects [26-28]. Therefore
it is not uncommon for parents to seek alternative treatments that do not have the same side effect profile as
MPH for their children [29-31].

for rheumatic disorders [44]. The process of extracting the
marine lipids from the P. canaliculus involves introducing
tartaric acid to the freeze dried powder form under a patented mussel stabilization process [45]. This method was
introduced following the inconsistent anti-inflammatory
effects of P. canaliculus from batch to batch [46]. A recent
systematic review on the freeze-dried powdered form of
the P. canaliculus showed mixed evidence for its effects
on osteoarthritis and rheumatoid arthritis, despite the
preservation of its marine lipids [42].

The omega-3 model

Lyprinol®/omega XL (PCSO-524®)

Observations by Dyerberg and Bang (1986) found that the
Eskimos of Greenland had low incidence rates of coronary
heart disease due to their high fat diets dominated by the
LC PUFA omega-3 [32]. This finding lead to further
research into the actions of omega-3 s on cognitive, behavioural and cardiovascular functions. Children with ADHD
have presented with lower levels of LC PUFAs in the blood
compared with normal populations and following supplementation, have shown improvements in symptoms related
to ADHD [15,17]. There are several reasons why these
children may have insufficient LC PUFAs such as: low
levels of the LC PUFAs obtained in the diet; the inefficient
conversion of shorter chain PUFAs (SC PUFAs) into LC
PUFAs; or the increased speed of metabolism of LC PUFAs
[33]. Omega-3 s increase the malleability of neuronal cells,
allowing more efficient nutrient exchange, increased cellular nourishment while also increasing fluidity of the blood
[34,35]. Increased membrane fluidity is associated with
faster neural transmission and more efficient biochemical
performance [34]. Fontani et al. (2005) discovered that
Omega-3 supplementation significantly improved higher
brain functions including sense of well-being, reactivity,
attention, cognitive performance, and mood in young
healthy adults [36].
The New Zealand Green Lipped Mussel (Perna
canaliculus) dates back to prehistoric times with coastal
Maori folklore claiming that consumption of the mussels
aided better health and fewer cases of arthritis than New
Zealanders residing further inland [37]. In a trial designed
in the 1960s to find cancer fighting therapies derived from
various marine organisms, researchers found patients
reported relief from symptoms of arthritis following the
administration of the powdered form of P. canaliculus
[38]. Since this time, research on P. canaliculus has
shown benefits to cardiovascular functioning and antiinflammatory processes [39-41]. Rheumatic disorders
are second only to heart disease in the ageing population, making them one of the most prevalent and costly
disorders in adults stimulating the increased research
into P. canaliculus [42]. With inconsistent research results using non-steroidal anti-inflammatories (NSAIDs)
[43] there has been significant use of natural medicines

Lyprinol®/Omega XL is a unique oil-based form of P.
canaliculus. A patented liquid carbon dioxide super
critical fluid extraction process (PCSO-524®) is unique
to Lyprinol®/Omega XL creating a highly condensed
form of the marine lipids of P. canaliculus [47]. Studies
on PCSO-524® have shown that this extract promotes
anti-leukotriene production, which can reduce symptoms of asthma in a study population of young children
[40]. It was this research that led to the confirmation of
the safety and tolerability of PCSO-524® in a population
of children as well as previous research demonstrating
its efficacy and safety in adults [41,48,49]. The unique
grouping of fatty acids in PCSO-524® has evolved as the
most potent group of Omega-3 lipids in blocking the 5 lipoxygenase metabolic pathway responsible for inflammation in the body [50]. It is this potent level of marine
lipids that may assist in the decreased PUFA levels in
children with symptoms of ADHD and similar developmental disorders and which is the major (but not only)
mechanistic basis of the current clinical trial.
Design

The study is a randomized, double-blind, placebocontrolled, 2-armed, parallel groups clinical trial with
children and adolescents randomized to receive either 3
capsules (if less than or equal to 45 kg) or 4 capsules
(if greater than 45 kg) of PCSO-524® or placebo.
Study aims and hypotheses

The objective of this trial is to examine whether 14 week
administration of a naturally occurring combination of
omega 3′s improves a range of cognitive (measured with
the COMPASS Cognitive Test Battery), mood (Brunel
Mood Scales), behavioural (Conners’ Parent Rating
Scale) and psychophysiological (electroencephalography
and steady state topography) measures in children aged
6–14 years with symptoms of inattention and hyperactivity relative to placebo. It is anticipated that this
project will conclude all testing in late 2013.
The primary aim of the current study is to examine
the levels of hyperactivity, impulsivity and inattention in
children aged 6 to 14 years of age before, during and
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after receiving a 14-week intervention of Lyprinol® compared to placebo. The primary outcome will be examining parental reports using the Conners’ Parent Rating
Scales −3 approximately every 4 weeks [51,52]. The
Conners’ Parent Rating Scales (CPRS) were developed as
a comprehensive checklist for acquiring parental reports
of the basic presenting problems [52]. Secondary outcomes will also include the acquisition of resting state
electroencephalography (EEG) in two states of eyes open
and eyes closed. Changes in brain wave ratios in key
areas of activity (prefrontal cortex) from baseline, week
8 and week 14 will also be examined to test the hypothesis that Lyprinol® will ameliorate the cortical hypoarousal that has been associated with ADHD [53] and
increase the ratio of alpha/beta waves compared to placebo.
Cognitive changes will be monitored using the Test
of Variables of Attention (TOVA) as well as the
Computerised Mental Performance Assessment System (COMPASS) [54]. Mood will be examined closely
using the Brunel Mood Scale (BRUMs) for adolescents [55].
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personally signed and dated informed consent indicating
that they have been informed of all pertinent aspects of
the trial; the parent will then get verbal consent from
the child.
Exclusion criteria

Medical diagnosis other than ADHD, Oppositional defiant disorder or similar behavioural disorders; Currently
taking any medication (other than stimulants if a formal
diagnosis of ADHD or other behavioural disorder is
present); Current or history of heart disease or high
blood pressure or diabetes; Health conditions that
would affect food metabolism including the following:
food allergies, kidney disease, liver disease and/or
gastrointestinal diseases (e.g. Irritable bowel syndrome, coeliac disease, peptic ulcers); Pregnant or
breast feeding; Unable to participate in all scheduled
visits, treatment plan, tests and other trial procedures
according to the protocol; Allergy to shellfish;
Epilepsy or photosensitive.
Treatments

Centres

All cognitive, mood and electrophysiological testing
will take place within the Swinburne Centre for Human
Psychopharmacology at Swinburne University in Victoria
Australia. Additional CPRS will be issued to the parents of
the participants who will be completing these questionnaires in the home environment in weeks 4, 10 and 18
(4 weeks post-administration of either Lyprinol or
placebo).
Participants

One hundred and fifty children aged between 6 and
14 years will complete either 14 week consumption of
Lyprinol/Omega XL or placebo. This age range is one of
the most common developmental stages for children to
experience increased levels of hyperactivity, impulsivity
and inattention and where 5-12% of children will receive
a diagnosis of ADHD. The study was ethically approved
by the Swinburne University Human Research Ethics
Committee (SUHREC Project 2010/175) and all participants will provide written informed consent. All procedures will be conducted in accordance with the
Declaration of Helsinki (2008) and the good clinical
practice (GCP) guidelines. The trial has been registered
with the Australian and New Zealand Clinical Trials
Registry (ACTRN12610000978066).
Inclusion and exclusion criteria
Inclusion criteria

Healthy, non-smoking males and females aged between
6 and 14 years; DSM-IV ADHD rating score above 15;
Fluent in English; Parent/legal guardian to provide a

The trial treatments are a naturally occurring combination of omega-3 s (Lyprinol®/Omega XL), and placebo.
Participants must take either 3 × or 4 × 260 mg capsules
in the morning (with breakfast). Principal Ingredients
per 260 mg capsule for the tablets are: Natural monounsaturated Olive oil - 100 mg; PCSO-524® GLM pat.
lipids (Eicosatetraenoic acid) - 50 mg; and Vitamin E
(D-alpha-Tocepherol) as antioxidant - 0.225 mg. The
Lyprinol capsules contain 18% EPA (46.8 mg) and 14%
DHA (36.4 mg) per capsule. The placebo capsule contains 35.5 mg of olive oil, 112 mg of lecithin, 12 mg of
coconut oil and 0.5 mg of 30% beta-carotene. Both
treatments are contained within tablets consisting of:
Gelatin; Sorbitol syrup; Glycerin. The placebo capsule
matches the Lyprinol® capsule in touch, taste, smell
and size.
In terms of the PCSO-524® component in each
Lyprinol/Omega XL capsule: Lyprinol® is a lipid extract of
the New Zealand green lipped mussel (Perna canaliculus).
Its major active constituents are unsaturated fatty acids.
The amount of these fatty acids ranges between 6.3% and
9.5% for the omega-6 class, and between 9.8% and 12.15%
for the omega-3 class. Lyprinol/Omega XL is currently
listed with the TGA of Australia as an anti-inflammatory.
Lyprinol/Omega XL has been shown to be a reproducible,
relatively stable, source of bioactive lipids with a much
greater potency than plant/marine oils currently used as
nutritional supplements to ameliorate signs of inflammation. Experimental studies have shown that lipid extracts
are effective at modulating 5’lipoxygenase and cyclooxygenase pathways, which are responsible for the
production of eiconoids, including leukotrienes and
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prostaglandins. The lipid extract of the New Zealand
green lipped mussel (Perna canaliculus), marketed under
the brand name Lyprinol and Omega XL, is rich in eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA),
omega-3 fatty acids that inhibit the metabolism of arachidonic acid. The compound is a mixture belonging to a
lipid group called sterol esters (SE). The fatty acids in the
SE fraction are mainly myristic acid, palmitic acid,
palmitoleic acid, stearic acid, oleic acid, linoleic acid,
EPA and DHA. The sterols found in this fraction
included cholesterol, cholesta-3, 5-diene, 26, 27dinoergostadienol, cholesta-5, 22-dien-3-ol, ergosta-5,
22-dien-3-ol.
Procedure

Participants will be randomly allocated to a coded treatment group and they will be given a supply of their
treatment. Participants will be required to take either 3
or 4 capsules daily (in the morning with breakfast) for
the following 14 weeks. The schedule for testing is
presented in Table 1. Weight plays a large role in the
digestion and absorption of nutrients giving reason for
the researcher’s choice of a weight limit (± 45 kg) over
that of an age limit in order to determine how many
capsules each child would take.
The first centre visit is a practice day where participants
complete screening questionnaires and familiarise themselves with the study procedures and tests. The next
Centre visit is a baseline session where participants
complete all tests (including the EEG) and are randomly
allocated to receive one of the two treatments (Lyprinol®/
placebo) for the next 14 weeks. Testing for all subsequent
centre visits will follow the same outline of their baseline

session with follow up visits at weeks 8 and 14. In between
these times, in weeks 4 and 10, the parents will complete
a CPRS and health questionnaire while the participants
will complete a mood questionnaire used in previous
visits. As the study progresses researchers will contact the
participants to determine compliance rates for the daily
use of the intervention as well as any adverse events.
Throughout the duration of the study, parents will be
required to complete the CPRS at home and bring in the
completed questionnaire each session or at the end of the
study. The participants will be given a treatment compliance diary and participants will need to mark each day
they take their treatment (this is to monitor for
compliance). At the end of the study, participants will be
required to return the compliance diary and symptom
checklists to the researcher as well as any remaining
treatment. The parent will also complete a seven-day food
diary in order to determine if the child’s omega-3 intake
from non-trial sources has remained consistent since
visit 1.
Post-treatment period: follow up

Participants’ parents will complete the CPRS and the
Brunel Mood Scale four weeks following the cessation of
Active or placebo administration to determine any
changes in mood or behaviour since ceasing treatment.
These scales can be completed by the parents independently or (more usually) with the child. Participants will
be questioned non-specifically for any Adverse Events
(AEs). A review of their Symptom Checklists will also
help to determine if a participant experienced an AE.
Figure 1 describes the flow of data collection for this
study.

Table 1 Behavioural and demographic measures

Structured Interview

V1

V2

Week 1

Week 2

Week 4

V3
Week 8

Week 10

V4
Week 14

Week 18

Practice

Centre

Home

Centre

Home

Centre

Home

X

X

X

X

X

X

X

X

X

X

X

(DSM ADHD Rating)
Conners’ Parent Rating Scale
Global Clinical Impressions Scale

X

Current Health & Medical Questionnaire

X

Demographics Questionnaire

X

Omega-3 Intake/Food Diary

X

X

X

X

X

Cognitive and Psychophysiological Measures
COMPASS cognitive battery

X

X

Test of Variables of Attention (TOVA)

X

X

Brunel Mood Scale (BRUMS)

X

X

X

X

X
X

X

X
X

X

EEG Resting State

X

X

X

Steady State Topography (SST)

X

X

X

X
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Figure 1 Lyprinol protocol flow diagram.

Randomization and safety

Randomization of participants to treatment groups
will be determined by random allocation. All 150 participants will be assigned to treatment group A or B using a
computer generated random number generator by a
neutral third party. Eligible, recruited participants will be
assigned a participant number. The treatment number
that has been placed next to the participant’s number
will be the allocated treatment for that individual.
Blinding will be achieved by enlisting a person outside of
the project to code the treatments, and maintain the key
to this code until data collection is completed. An emergency code break envelope will be provided to the
principle investigator which will only be opened in case
of emergency. Participants’ parents will also be given a
weekly symptom checklist to complete to monitor for

any adverse events. Researchers will be blinded to the
treatment conditions.
Primary outcome

The CPRS will be used to record parents’ ratings of
inattention and hyperactivity. The CPRS is to be filled
out by the parent at home on weeks 2, 4, 8, 10, 14 and
18 [56]. Researchers involved exclusively in this trial will
score and enter the data from each CPRS following the
participants’ completion of the trial. The researchers are
blinded to treatment allocation.
Secondary outcome measures

The Tests of Variables of Attention (TOVA) will assess
symptoms of inattention and impulsivity. The TOVA is a
computer-based assessment of inattention [54].
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COMPASS (computerised mental performance assessment
system)

The COMPASS battery has been developed to include
tests which have been shown to be sensitive to nutritional manipulations. The tasks in this study are
designed to allow assessment across the major cognitive
domains i.e. attention, working memory, secondary
memory and executive function. Parallel versions of each
of the following tasks allowed for multiple testing. Previous studies have used a similar customized battery in
testing adolescents and their responses to dietary changes
[57-63]. The following cognitive COMPASS tasks will be
administered: Word presentation; Immediate word recall;
Picture presentation; Simple reaction time; Choice reaction time; Numeric working memory; Delayed word recall;
Delayed word recognition; Delayed picture recognition
(see Table 2 for task descriptions).
Mood

The Brunel Mood Scale (BRUMS) was derived from the
Profile of Mood States mood scale [64] and contains 24
simple mood descriptors such as angry, energetic,
nervous, and unhappy. The BRUMS (formerly known as
the profile of Mood States – Adolescents or POMS-A)
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was designed for purely adolescent populations and the
validation process can be found in Terry et al [55,65].
Diet

At the beginning of the trial the parent will complete a
Food Frequency Questionnaire (FFQ) that will provide a
detailed description of the child’s food intake. In week 4
of the trial the parent will complete a 7-day food diary
consisting of what the child has had to eat for breakfast,
lunch and dinner as well as any significant snacks
throughout those days. This diary will be compared to
the FFQ to determine any changes in diet that may have
occurred while in the study.
Resting electroencephalography (EEG) and steady state
topography (SST)

Brain electrical activity will be recorded from 64 sites on
the scalp, including all of the International 10–20 positions
and sites located midway between the 10–20 locations. All
electrodes will be held in place using an electrocap. Electrode impedance will vary from 2.5 kohmsto 8.5 kohms
when measured at 40 Hz. The average of both earlobes
will serve as a reference. EEG will be amplified and bandpass filtered (3 dB down at 0.1 Hz and 30 Hz) prior to

Table 2 COMPASS task descriptions and scoring
Task

Task description

Word
presentation

Individual words are presented sequentially on the monitor. Stimulus duration
was 1 s, as is the inter-stimulus interval.

Task scoring

Immediate
word recall

The participant is allowed 60 s to write down as many of the words as
possible.

Picture
presentation

Twenty line-drawings of everyday items are presented on the computer screen.
Stimulus duration is 3 s, with a 1 s inter-stimulus duration.

Simple
reaction time

A series of upwards pointing arrows appear in the centre of the screen with a The task is scored in Response times (recorded in
randomly varying inter-stimulus interval between 1 and 3 s. The participant will milliseconds)
press the space bar as quickly as possible to the on screen appearance of each
stimulus.

Choice
reaction time

Arrows pointing to the left or right are presented in the centre of the screen
with a randomly varying inter-stimulus interval of 1–3 s. The volunteer presses
the corresponding ‘left’ or ‘right’ cursor key on the computer keyboard as
quickly as possible.

The task is scored for accuracy (%) and reaction
time (ms).

Numeric
working
memory

A series of five digits is presented on the computer screen sequentially for the
participants to hold in their memory. This is followed by a series of 30 probe
digits. The participants indicate whether or not the digit was from the original
series by pressing corresponding keys labelled ‘yes’ and ‘no’. This is repeated
three further times with different stimulus sets.

Reaction times (ms) and accuracy (% correct) are
measured

Delayed word
recall

Approximately 20 min after the word presentation, the participant is allowed
60 s to write down as many of the items from word presentation as possible.

The task is scored as for immediate word recall.

Delayed word
recognition

Word recognition is tested by representation of the words from the original list The task is scored for accuracy (%), and reaction
randomly interspersed with an equal number of distracter words. Participants
time (ms).
respond either ‘yes’ or ‘no’ by pressing corresponding key to indicate whether
the word had previously been presented or not.

Delayed
picture
recognition

Picture recognition is tested by the presentation of the original drawings and
an equal number of distracters in random order. Participants respond either
‘yes’ or ‘no’ by key press in order to indicate whether the picture had been
presented previously.

The task is scored for number of correct answers,
errors and intrusions and the resulting score is
converted into a percentage

The task is scored for accuracy (%) and reaction
time (ms).
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digitisation to 12-bit accuracy at a rate of 200 Hz. Changes
in brain wave ratios in key areas of activity will also be examined to test the hypothesis that Lyprinol® will ameliorate
the cortical hypoarousal that has been associated with
ADHD [11,53,66-71]. The stimulus used to evoke the SST
will be a diffuse 13 Hz sinusoidal flicker superimposed on
the visual field by a pair of goggles. The goggles will comprise two half-silvered mirrors that reflect two lightemitting diode arrays over the subject’s visual field,
subtending a horizontal angle of 160 degrees and a vertical
angle of 90 degrees. The maximum intensity at the peak of
the stimulus waveform will be 5.0 cd/m2 and the modulation depth will be 45%. In order to control for variations in
vigilance, subjects will perform a low level cognitive task.
Signal processing of EEG data

Two hundred and fifty seconds of EEG data will be
gathered for each subject in each condition, yielding a
frequency resolution of 0.004 Hz. The SST recorded at
each electrode will be determined via Fourier analysis
centred at 13 Hz with a width of 0.004 Hz. The sine and
cosine Fourier components will be used to determine
the amplitude and phase of the SST [72]. Data will be
checked for artefact using techniques described in
Silberstein et al., (1995) [73].
Global clinical impression scale (GCI)

Amongst the most widely used of extant brief assessment
tools in psychiatry, the GCI is a 3-item observer-rated
scale that measures illness severity (CGIS), global improvement or change (GCIC) and therapeutic response. The
GCI has proved to be a robust measure of efficacy in many
clinical drug trials, and is easy and quick to administer.
The GCI is rated on a 7-point scale, with the severity of
illness scale using a range of responses from 1 (normal)
through to 7 (amongst the most severely ill patients).
GCIC scores range from 1 (very much improved) through
to 7 (very much worse). Treatment response ratings
should take account of both therapeutic efficacy and
treatment-related adverse events and range from 0 (marked
improvement and no side-effects) and 4 (unchanged or
worse and side-effects outweigh the therapeutic effects).
Each component of the GCI is rated separately; the
instrument does not yield a global score.
Power and statistical analysis

The sample size for this study is 150 participants with 75
participants in each arm (Lyprinol vs Placebo). A power
calculation to determine the sample size was performed
using Gpower 3.12. Based on previous studies looking at
omega-3 supplementation in children with ADHD such as
Sinn & Bryan (2007) who had an n of 132 and were able
to find statistical significance in terms of the CPRS [15], a
small to medium effect size (F = .20) on the Conners’ was
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postulated for Lyprinol over placebo from baseline to
week 18 over six time points (critical F = 3.92, with an
alpha probability of 0.05 and beta power of 0.80). This
provided a sample size of 118; with drop-outs being
projects at approximately 20%, a sample of 150 participants was estimated. Repeated Measures ANOVAs with
an n of 150 (75 per group) will allow the researchers to
account for any confounding variables in the trial including within-group and between-group variability. Any
heterogeneous variables showing statistically significant
differences at baseline will be co-varied in order to negate
their influence on the power of the study.

Conclusions
Attention-deficit/hyperactivity disorder (ADHD) is the
most prevalent developmental disorder in school aged
children [1,3]. The symptoms of ADHD include hyperactivity, impulsivity, and inattention. The prevalence rate
of ADHD within Western cultures is between 5% and
12%, representing the most common neurodevelopmental
disorder among school-aged children, with an estimated
50% of these children retaining ADHD symptoms into
adulthood and for the rest of their lives [1,3] and less than
5% of this demographic attaining a university degree [18].
Interventions which are efficacious and which have no or
little side effects are urgently required for both children
and adolescents who fall within the clinical classification
of ADHD and also who have high levels of the symptoms
of inattention and impulsivity but who fall below the classification of ADHD. One treatment model is based on the
reduced levels of LC-PUFAs in the plasma of ADHD
children compared to normals [6,13-15,17]. This has led
to extensive research examining the efficacy of omega-3
supplementation as a natural alternative to methylphenidate (MPH e.g., Ritalin®) and other stimulant and nonstimulant pharmaceuticals [16,17]. In the current study
we will administer either placebo or a novel and patented
marine lipid from the New Zealand Green Lip Mussel
(PCSO-524®) to 150 children and adolescents with ADHD
or high levels of inattention and hyperactivity for 14 weeks.
A range of behavioural and neurophysiological measures
will be undertaken. The results of the study will aid our
understanding of the role of LC-PUFAs in improving
behavioural, cognitive and physiological variables in
children and adolescents and whether this intervention is
efficacious.
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